Your browser doesn't support javascript.
loading
Long-Term Outcomes of Fractionated Stereotactic Proton Therapy for Vestibular Schwannoma: A Case Series.
Zhu, Simeng; Rotondo, Ronny; Mendenhall, William M; Dagan, Roi; Lewis, Debbie; Huh, Soon; Knox, Glenn; Tavaniepour, Daryoush; Sandhu, Sukhwinder; Rutenberg, Michael S.
  • Zhu S; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Rotondo R; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Mendenhall WM; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Dagan R; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Lewis D; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Huh S; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Knox G; Department of Otolaryngology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Tavaniepour D; Department of Neurosurgery, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Sandhu S; Department of Radiology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Rutenberg MS; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
Int J Part Ther ; 4(4): 37-46, 2018.
Article en En | MEDLINE | ID: mdl-31773014
PURPOSE: Evaluate clinical outcomes in patients with vestibular schwannoma (VS) treated with fractionated proton therapy (PT) at a single institution. MATERIALS AND METHODS: We retrospectively reviewed the medical records of patients treated with fractionated PT for definitive management of VS between November 2007 and December 2013 at our institution. No patient had received prior treatment for VS. Patients received 50.4 Gy in 28 fractions using passively scattered PT. Pretreatment and posttreatment hearing status, tumor dimensions, and cranial nerve V and VII function were evaluated. Hearing status was graded as nonserviceable or serviceable, defined as Gardner-Robertson grade I or II and the ability to use a telephone with the treated ear. Toxicities were prospectively evaluated using Common Terminology Criteria for Adverse Events, version 4.0. RESULTS: Fourteen patients with 14 lesions (8 men, 6 women) were included in the analysis. Median age at treatment was 60 years (range, 24-74 years). Median clinical follow-up for living patients was 68 months (range, 36-106 months). Mean maximal tumor dimension was 2.1 cm (range, 0.5-3.8 cm). Mean tumor volume was 6.4 cm3 (range, 0.3-16.0 cm3). One patient died of unrelated causes 5 months after treatment, and 2 had subsequent surgical resections due to radiographic and/or clinical progression. The actuarial 3-year local control rate was 85%. There were no cranial nerve V or VII injuries. Two of 6 patients (33%) with serviceable hearing at the time of treatment retained serviceable hearing. Three patients (21%) demonstrated radiographic tumor regression on brain magnetic resonance imaging after a median of 26 months (range, 2-113 months). No acute toxicity of grade 3 or above was reported. CONCLUSION: Fractionated PT for VS is well tolerated and provides good local control. Improvements in proton delivery techniques and patient selection may enable improved outcomes.
Palabras clave